A Single-center, Non-randomized, Open-label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer.
Latest Information Update: 03 Mar 2026
At a glance
- Drugs XH 001 (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
Most Recent Events
- 25 Feb 2026 Planned primary completion date changed from 1 Nov 2027 to 1 Jun 2028.
- 25 Feb 2026 Status changed from not yet recruiting to recruiting.
- 29 Dec 2025 New trial record